NCT05987072View on ClinicalTrials.gov

A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Respiratory Syncytial Virus Infection
Interventions
DRUG

Sisunatovir

Will be given as a single dose on Day 1 in a fasted state followed by repeated twice daily doses (200 mg BID, Q12 hours) from Days 4-7 plus 1 morning dose on Day 8 in a fed state

Trial Locations (3)

200040

Huashan Hospital, Fudan University, Shanghai

Huashan Hospital, Shanghai

201107

Huashan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05987072 - A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults. | Biotech Hunter | Biotech Hunter